Core Concepts
Breast cancer receptor testing disparities exist among specific populations.
Abstract
The study analyzed over 300,000 patients with invasive breast cancer to identify gaps in receptor testing among certain groups.
TOPLINE:
- Testing lags in older women, Black women, rural area residents, and those with distant or unstaged cancers.
METHODOLOGY:
- Guidelines recommend estrogen, progesterone, and HER2 receptor status testing.
- Data from 2012-2016 on 321,913 women with invasive breast cancer were reviewed.
TAKEAWAY:
- 4.7% of women had missing components of receptor status.
- Odds of missing components were higher in older women, Black women, and those with distant or unstaged cancers.
IN PRACTICE:
- Missing components persist, especially in certain socioeconomic populations.
- Study results can aid in targeting affected populations to reduce health disparities.
SOURCE:
- Led by Julie Stephens, MS, of Ohio State University, the study was published in JAMA Network Open.
LIMITATIONS:
- Data do not include severe comorbidities or recent trends post-2016.
DISCLOSURES:
- Funded by the Ohio Department of Health, with senior investigator Electra Paskett, PhD, having industry ties.
Stats
Overall, 4.7% of women had missing components of receptor status.
Odds of missing components were higher in certain groups: older women, Black women, women with distant or unstaged cancers.
Cases reported by different facilities were more likely to have missing components of receptor status.
Missing components were more likely for women in rural areas and those with unknown insurance status.
Quotes
"The results of this study may help clinicians, public health practitioners, and policymakers target affected populations to minimize or eliminate this critical health disparity and help save more lives." - Authors